Chemotherapy has a modest benefit for some cancers and no benefit for others. The evidence is more nuanced than oncologists typically present — and the risks are substantial.

The Evidence for Chemotherapy

A landmark 2004 study by Morgan et al. analyzed the contribution of chemotherapy to 5-year survival in adults with cancer in Australia and the United States. The findings were striking:

  • Overall contribution of chemotherapy to 5-year survival: 2.3% in Australia, 2.1% in the United States
  • For most common cancers (lung, colon, breast, prostate), the contribution was less than 2%
  • For some cancers (testicular, Hodgkin's lymphoma, childhood leukemia), the contribution was substantial

This does not mean chemotherapy is never beneficial — for some cancers, it is clearly effective. But the routine use of chemotherapy for most common cancers is not supported by the evidence.

The overall contribution of chemotherapy to 5-year survival in adults with cancer is 2.3%. For most common cancers, the contribution is less than 2%.

The Problem with Clinical Trials

Chemotherapy trials typically measure:

  • Tumor response rate (does the tumor shrink?)
  • Progression-free survival (how long before the cancer grows?)
  • Overall survival (how long does the patient live?)

The problem is that tumor response and progression-free survival do not always translate into improved overall survival. A drug can shrink a tumor without extending the patient's life — and the side effects of the drug may reduce quality of life.

The Side Effect Problem

Chemotherapy kills rapidly dividing cells — both cancer cells and normal cells. The side effects include:

  • Bone marrow suppression (anemia, infection risk, bleeding)
  • Nausea and vomiting
  • Hair loss
  • Peripheral neuropathy
  • Cognitive impairment ("chemo brain")
  • Increased risk of secondary cancers

For cancers where chemotherapy has minimal survival benefit, these side effects represent a significant harm-to-benefit imbalance.

Cancers Where Chemotherapy Works

Chemotherapy has clear, substantial benefit for:

  • Testicular cancer (cure rate >95%)
  • Hodgkin's lymphoma (cure rate >85%)
  • Childhood acute lymphoblastic leukemia (cure rate >85%)
  • Some types of non-Hodgkin's lymphoma

For these cancers, chemotherapy is clearly indicated.

The Diet-Cancer Connection

The evidence that diet influences cancer risk and progression is strong. Cancer cells are metabolically distinct: they preferentially consume glucose and fructose (the Warburg effect). A low-sugar, low-carbohydrate diet may starve cancer cells while sparing normal cells.